United States v. Abbott Laboratories

District Court, S.D. California·Decided November 20, 2023·No. 3:20-cv-00286·Unknown

Opinion

2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 UNITED STATES OF AMERICA, et al. ex rel. Case No.: 20cv286-W (MSB) Everest Principals, LLC, 12 ORDER DENYING DEFENDANTS’ Plaintiffs, 13 MOTION TO COMPEL PRODUCTION OF v. DISCLOSURE STATEMENT AND POST- 14 DISCLOSURE GOVERNMENT ABBOTT LABORATORIES, et al., 15 COMMUNICATIONS Defendants. [ECF NOS. 113 & 114] 16

17 18 This is a qui tam case, wherein Plaintiff-Relator, Everest Principals, LLC (“Relator”) 19 maintains causes of action against Defendants Abbott Laboratories, Abbott 20 Cardiovascular Systems, Inc., Abbott Vascular, Inc., and Abbott Laboratories, Inc. 21 (collectively “Abbott” or “Defendants”) on behalf of the United States of America 22 (“U.S.”) and several states for violations of the federal False Claims Act (“FCA”) and 23 analogous state laws. (See ECF No. 85 at 6.) Now pending before this Court is 24 Defendants’ “Motion to Compel Relator’s Disclosure Statement and Subsequent 25 Submissions/Communications.” (ECF No. 114.) Based on the parties’ joint request, both 26 Relator and Defendants submitted their respective briefing on this dispute on October 27 20, 2023. (ECF Nos. 112-14.) 2 Opposition thereto [ECF No. 113], and the authorities cited therein, the Court DENIES 3 Defendants’ Motion to Compel for the reasons described below. 4 I. RELEVANT BACKGROUND 5 The False Claims Act (“FCA”) encourages insiders to disclose fraud against the 6 government through a qui tam provision that permits private individuals (known as 7 “relators”) to bring civil actions on the government’s behalf and retain a portion of any 8 award. Ebeid ex rel. United States v. Lungwitz, 616 F.3d 993, 995 (9th Cir. 2010). When 9 filing such a complaint, a relator must serve on the Government “[a] copy of the 10 complaint and written disclosure of substantially all material evidence and information 11 the person possesses.” 31 U.S.C. § 3730(b)(2). The purpose of this disclosure 12 requirement is to give the United States enough information to make a well-reasoned 13 decision whether to intervene or allow the relator to proceed alone with the action. 14 United States ex rel. Bagley v. TRW, Inc., 212 F.R.D. 554, 555 (C.D. Cal. 2003) (internal 15 citations omitted). 16 Relator is a limited liability company whose sole member, Lisa Knott,1 was 17 employed by Defendants as a Therapy Development Specialist in its Structural Heart 18 Division from August 2015 to April 2017. (See ECF No. 85 at 7; ECF No. 104 at 2.) 19 Pursuant to 31 U.S.C. §§ 3729, et seq., Relator filed its original Complaint under the FCA 20 under seal on February 14, 2020. (ECF No. 1.) The Relator summarized its allegations 21 therein as follows: “Defendants engaged in an unlawful, systematic and nationwide 22 scheme of providing illegal kickbacks to physicians and hospitals in the form of, inter 23 alia, patient referrals, honoraria for sham speaker programs and events, free lavish 24 meals, cocktail parties, and free patient marketing services to induce physicians and 25 hospitals to use Abbott’s MitraClip® device (“MC Device”) to certain cardiac patients 26 27 2 Statute (“AKS”)], and analogous state laws and statutes.” (Id. at 3.) Relator submitted a 3 copy of its Complaint and a “written disclosure of substantially all material evidence and 4 information the person possesses” (“Disclosure Statement”) to the Department of 5 Justice as required by the False Claims Act. (ECF No. 113 at 3; ECF No. 114-1 at 5); 31 6 U.S.C. § 3730(b)(2). The Disclosure Statement included an unspecified number of 7 attachments. (See ECF No. 113-2 at 4.) Relator additionally made subsequent periodic 8 communications and status updates to the Government, who remains the real party in 9 interest in this litigation. (ECF No. 113 at 3; ECF No. 114-1 at 5.) 10 The government entities declined to intervene, and the Court unsealed the 11 Complaint on March 25, 2021. (ECF Nos. 8, 9.) After three motions to dismiss on the 12 pleadings, (see ECF Nos. 30, 45, 59), discovery opened in this case on February 15, 2023. 13 (See ECF No. 69 at 3 (setting Rule 26(f) Conference deadline of February 15, 2023)); Fed. 14 R. Civ. P. 26(d)(1) (“A party may not seek discovery from any source before the parties 15 have conferred as required by Rule 26(f). . . .”). The Court held an Early Neutral 16 Evaluation and Case Management Conference on April 17, 2023 and issued a Scheduling 17 Order the following day. (See ECF Nos. 76, 77.) Relator filed its operative Third 18 Amended Complaint (“Operative Complaint”) on May 23, 2023, in which it added to its 19 summary that Defendants’ purported “nationwide scheme of kickbacks” also included 20 patient practice building and “rewards in the form of clinical trial opportunities.” (ECF 21 No. 85 at 6-7.) 22 On July 12, 2023, Defendants served Relator with their Requests for Production – 23 Set One (“RFP”). (ECF No. 114-2 at 2.) Relevant here, RFP No. 4 sought “[a]ll 24 communications between [Relator] and any government agency relating to Abbott or 25 this litigation.” (Id. at 2-3.) RFP No. 5 sought “[a]ll communications (excluding 26 privileged communications solely between you and your counsel of record in this action) 27 relating to any allegation that Abbott violated any law or to the claims or allegations of 2 protected by the attorney-client privilege, the common interest privilege, the joint 3 prosecution privilege, or which constitute attorney work product that are protected 4 from disclosure in discovery.” (ECF No. 114-4 at 3-4.) Relator indicated it did not have 5 any non-privileged documents responsive to RFP No. 4, and otherwise noted “that 6 documents will be withheld on the basis of its objections.” (Id. at 4-5.) 7 On August 14, 2023, Defendants served interrogatories on Relator. (ECF No. 114- 8 5.) One interrogatory asked Relator to “[i]dentify all Government Agencies and any 9 other governmental bodies with which You communicated relating to Abbott, this case, 10 or any other litigation filed or contemplated by You against Abbott.” (ECF No. 114-5 at 11 6.) After raising overbreadth and privilege objections, Relator listed eleven such 12 government entities and indicated it would produce responsive, non-privileged 13 documents. (ECF No. 114-6 at 3-4.) 14 After meeting and conferring with one another and engaging in an informal 15 discovery conference with the Court, Defendants now move to compel production of 16 Relator’s Disclosure Statement and subsequent communications/submissions to the 17 government (together, “Government Communications”) as responsive to the RFPs 18 discussed above. (ECF No. 114; see also ECF Nos. 105, 106, 112.) Pursuant to a briefing 19 schedule requested by the parties, Defendants filed their Motion to Compel the same 20 day that Relator filed its Opposition thereto, on October 20, 2023. (ECF Nos. 113, 114.) 21 II. DISCUSSION 22 Defendants claim that Relator’s Government Communications are relevant and 23 critical to Abbott’s defense and should be produced. (ECF No. 114-1 at 7.) Relator 24 argues that the Government Communications are completely protected under the work 25 product and common interest doctrines. (ECF No. 113 at 2.) Defendants assert that 26 they have demonstrated substantial need and undue hardship sufficient to justify the 27 disclosure of fact work product, a conclusion Relator contests. (Compare ECF No. 114-1 2 why they have a substantial need for the documents or why they cannot obtain the 3 substantial equivalent of the documents by other means”) (quoting United States ex rel.

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Abbott Laboratories, (S.D. Cal. 2023).

United States v. Abbott Laboratories (United States v. Abbott Laboratories) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Ebeid Ex Rel. United States v. Lungwitz
616 F.3d 993 (Ninth Circuit, 2010)
US Ex Rel. O'Keefe v. McDonnell Douglas Corp.
918 F. Supp. 1338 (E.D. Missouri, 1996)
Goehring v. Brophy
94 F.3d 1294 (Ninth Circuit, 1996)
Hallett v. Morgan
296 F.3d 732 (Ninth Circuit, 2002)
United States ex rel. Bagley v. TRW Inc.
212 F.R.D. 554 (C.D. California, 2003)
United States ex rel. Carter v. Halliburton
266 F.R.D. 130 (E.D. Virginia, 2010)
United States v. Guzman
160 F.R.D. 6 (D. Massachusetts, 1995)
Soto v. City of Concord
162 F.R.D. 603 (N.D. California, 1995)
United States ex rel. Burns v. Family Practice Associates
162 F.R.D. 624 (S.D. California, 1995)
United States ex rel. Burroughs v. DeNardi Corp.
167 F.R.D. 680 (S.D. California, 1996)